Abstract
Alzheimers Disease (AD) is caused by the deposition of insoluble and toxic amyloid peptides (Aβ) in the brain leading to memory loss and other associated neurodegenerative symptoms. To date there is limited treatment options and strategies for treating AD. Studies have shown that clearance of the amyloid plaques from the brain and thus from the blood could be effective in stopping and or delaying the progression of the disease. Small peptides derived from the Aβ- 42 sequence, in particular KLVFF, have shown to be effective binders of Aβ peptides and thus could be useful in delaying progression of the disease. We have taken advantage of this property by generating the retro-inverso (RI) version of this peptide, ffvlk, in different formats. We are presenting a new detox gel system using poly ethylene glycol (PEG), polymerized and cross linked with the RI peptides. We hypothesize that detox gel incorporating RI peptides will act like a ‘sink’ to capture the Aβ peptides from the surrounding environment. We tested these detox gels for their ability to capture biotinylated Aβ-42 peptides in vitro. The results showed that the detox gels bound Aβ-42 peptides effectively and irreversibly. Gels incorporating the tetramer RI peptide exhibited maximum binding capacity. The detox gel could be a potential candidate for treatment strategies to deplete the brain of toxic amyloid peptides.
Keywords: Alzheimer's disease, amyloid, Aβ, detox gels, RI peptides
Current Alzheimer Research
Title: Detoxification Depot for β -Amyloid Peptides
Volume: 5 Issue: 1
Author(s): Pazhani Sundaram, Ranjini K. Sundaram, Chinnaswamy Kasinathan and Stanley Stein
Affiliation:
Keywords: Alzheimer's disease, amyloid, Aβ, detox gels, RI peptides
Abstract: Alzheimers Disease (AD) is caused by the deposition of insoluble and toxic amyloid peptides (Aβ) in the brain leading to memory loss and other associated neurodegenerative symptoms. To date there is limited treatment options and strategies for treating AD. Studies have shown that clearance of the amyloid plaques from the brain and thus from the blood could be effective in stopping and or delaying the progression of the disease. Small peptides derived from the Aβ- 42 sequence, in particular KLVFF, have shown to be effective binders of Aβ peptides and thus could be useful in delaying progression of the disease. We have taken advantage of this property by generating the retro-inverso (RI) version of this peptide, ffvlk, in different formats. We are presenting a new detox gel system using poly ethylene glycol (PEG), polymerized and cross linked with the RI peptides. We hypothesize that detox gel incorporating RI peptides will act like a ‘sink’ to capture the Aβ peptides from the surrounding environment. We tested these detox gels for their ability to capture biotinylated Aβ-42 peptides in vitro. The results showed that the detox gels bound Aβ-42 peptides effectively and irreversibly. Gels incorporating the tetramer RI peptide exhibited maximum binding capacity. The detox gel could be a potential candidate for treatment strategies to deplete the brain of toxic amyloid peptides.
Export Options
About this article
Cite this article as:
Sundaram Pazhani, Sundaram K. Ranjini, Kasinathan Chinnaswamy and Stein Stanley, Detoxification Depot for β -Amyloid Peptides, Current Alzheimer Research 2008; 5 (1) . https://dx.doi.org/10.2174/156720508783884684
DOI https://dx.doi.org/10.2174/156720508783884684 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mephedrone Concentrations in Cases of Clinical Intoxication
Current Pharmaceutical Design Absorption Cooling: A Review of Lithium Bromide-Water Chiller Technologies
Recent Patents on Mechanical Engineering Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews Use of fMRI and Structural Equation Modeling for Studying Interconnected Brain Areas within a Hypothetical Network
Current Medical Imaging “Medical Clearance” of Psychiatric Patients in the Emergency Department
Adolescent Psychiatry Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents
Current Proteomics HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?
Current Alzheimer Research A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Investigation of Thrombin Activity with PAR 1-based Fluorogenic Peptides
Protein & Peptide Letters AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders
Current Topics in Medicinal Chemistry Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research Control and Role of Plateau Potential Properties in the Spinal Cord
Current Pharmaceutical Design Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
CNS & Neurological Disorders - Drug Targets Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets